Luteolin alleviates methionine–choline-deficient diet-induced non-alcoholic steatohepatitis by modulating host serum metabolome and gut microbiome

Abstract

Background and purposePrevious studies have indicated the protective effects of luteolin against non-alcoholic steatohepatitis (NASH), but the definite underlying mechanism still remains unclear. This study aimed to explore the metabolomic and metagenomic signatures of NASH with luteolin supplementation.Experimental approachMice were fed with a methionine–choline-deficient (MCD) diet containing 0.05% luteolin for 6 weeks. NASH severity was determined based on the liver histological observations, serum and hepatic biochemical measurements. Targeted metabolomics was conducted to identify differential metabolites in mice serum. 16S rRNA sequencing was conducted to assess the gut microbiota composition and function in mice colon.ResultsIn detail, luteolin treatment significantly alleviated MCD diet-induced hepatic lipid deposition, liver function damage, and oxidative stress. Targeted plasma metabolomics revealed that 5-hydroxyindole, LPE (0:0/22:5), indole 3-phosphate, and N-phenylacetylphenylalanine were remarkably elevated, and homogentisic acid, thiamine, KN-93, PC (16:1e/8, 9-EpETE), carnitine C9:1-OH, FFA (18:4) and carnitine C8:1 were significantly decreased in NASH group as compared to normal group, which could be profoundly reversed after luteolin treatment. 16S rRNA sequencing indicated that luteolin supplementation significantly increased Erysipelatoclostridium and Pseudomonas as well as decreased Faecalibaculum at genus level. Most importantly, a negative association between thiamine and Faecalibaculum was observed based on Spearman's correlation analysis, which may play an important role in the preventive effects of luteolin against NASH.ConclusionCollectively, luteolin may alleviate the NASH by modulating serum metabolome and gut microbiome, which supports its use as a dietary supplement for NASH prevention.

Naringenin prevents non‐alcoholic steatohepatitis by modulating the host metabolome and intestinal microbiome in MCD diet‐fed mice

“…For the serum metabolome, an instrument of ultra‐performance liquid chromatography (UPLC, ExionLC AD) and tandem MS (triple quadrupole‐linear ion trap MS (QTRAP®)) was used, and two separate LC conditions, including T3 and Amide modes, were employed in the analysis. The LC and MS conditions were consistent with our previous publications (Cao et al, 2019, 2021; Guo et al, 2022). Based on the targeted metabolomics platform and self‐built database, we compared and found differences in serum metabolic profiles between different groups.…”

“…The balance between gut microbiome and host metabolome has become recognized as important in the maintenance of physiological function and has become a target in treating various diseases (Cao, Hu, et al, 2023; Guo et al, 2022; Zhang et al, 2022). Currently, the integrated analysis of metabolomics and 16S ribosomal RNA (rRNA) microbial gene sequencing is a common approach to studying the underlying mechanisms of drug action or disease pathology (Yang et al, 2019).…”

A holistic comparison of flavor signature and chemical profile in different harvesting periods of Chrysanthemum morifolium Ramat. based on metabolomics combined with bioinformatics and molecular docking strategy

“…Luteolin alleviated hepatitis by regulating serum metabolites and intestinal microorganisms. 46 Apigenin possessed anticancer, antioxidant, and anti-inflammatory effects, including inhibiting cell growth and proliferation in Hep3B cells. 47 It was reported that diosmetin could inhibit the progression of cancer.…”

Transcriptomics and metabolomics analysis reveal the anti-oxidation and immune boosting effects of mulberry leaves in growing mutton sheep

“…Carnitine plays a key role not only in fatty acid b-oxidation, but also in immunity enhancement and disease resistance. Guo et al (41) found that carnitine C8:1 was significantly decreased the in non-alcoholic steatohepatitis group, and this could be profoundly reversed after luteolin treatment. Studies have reported decreased serum acyl-carnitine concentrations in patients with cancer (42).…”